BioPharma Dive November 9, 2023
The pharma paid $400 million to license the drug from Hutchmed earlier this year in an effort to bolster its oncology business.
Dive Brief:
- The Food and Drug Administration on Wednesday approved a new targeted therapy for metastatic colon cancer, granting an OK to Furzaqla from Takeda.
- The drug is cleared for adults with previously treated metastatic colorectal cancer, regardless of what protein markers their tumors express. Takeda claims it’s the first drug that targets all three subtypes of an important cellular regulator known as VEGF.
- Known scientifically as fruquintinib, Fruzaqla won its clearance several weeks ahead of the FDA’s target Nov. 30 decision date. It’s already approved for colon cancer in China, where it’s marketed as Elunate by...
Today's Sponsors
Today's Sponsor